These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34948159)

  • 1. Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.
    López Y; Muñoz L; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    Int J Antimicrob Agents; 2020 Sep; 56(3):106082. PubMed ID: 32659467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    PLoS One; 2019; 14(10):e0223326. PubMed ID: 31596898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.
    Wang LH; Cheng H; Hu FL; Li J
    World J Gastroenterol; 2010 May; 16(18):2272-7. PubMed ID: 20458765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozenoxacin: a review of preclinical and clinical efficacy.
    Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6389-92. PubMed ID: 24080666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
    Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
    Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiological profile of ozenoxacin.
    Morrissey I; Cantón R; Vila J; Gargallo-Viola D; Zsolt I; Garcia-Castillo M; López Y
    Future Microbiol; 2019 Jun; 14():773-787. PubMed ID: 31132895
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
    Tato M; López Y; Morosini MI; Moreno-Bofarull A; Garcia-Alonso F; Gargallo-Viola D; Vila J; Cantón R
    Diagn Microbiol Infect Dis; 2014 Mar; 78(3):263-7. PubMed ID: 24321353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
    Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
    Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
    Sahu JK; Mishra AK
    Curr Drug Discov Technol; 2019; 16(3):259-264. PubMed ID: 29732990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
    Kanayama S; Okamoto K; Ikeda F; Ishii R; Matsumoto T; Hayashi N; Gotoh N
    J Infect Chemother; 2017 Jun; 23(6):374-380. PubMed ID: 28389164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.
    Oka D; Changkwanyeun R; Yamaguchi T; Nakajima C; Suzuki Y; Matsumoto M
    J Antimicrob Chemother; 2022 Nov; 77(12):3248-3255. PubMed ID: 36101508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.